NOVAVAX, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.89 USD | 0.00% |
|
-9.53% | -18.96% |
| Apr. 15 | Sector Update: Health Care Stocks Gain Monday Afternoon | MT |
| Apr. 15 | Global markets live: Goldman Sachs, Apple, Salesforce, Boeing Tesla... |  |
Financials (USD)
| Sales 2024 * | 850M | Sales 2025 * | 986M | Capitalization | 544M |
|---|---|---|---|---|---|
| Net income 2024 * | -90M | Net income 2025 * | -82M | EV / Sales 2024 * | 0.04 x |
| Net cash position 2024 * | 510M | Net cash position 2025 * | 482M | EV / Sales 2025 * | 0.06 x |
| P/E ratio 2024 * |
-5.31
x | P/E ratio 2025 * |
-73.5
x | Employees | 1,543 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.33% |
More Fundamentals
* Assessed data
More news
Latest transcript on Novavax, Inc.
More recommendations
More press releases
More news
| 1 week | -9.53% | ||
| Current month | -18.62% | ||
| 1 month | -24.32% | ||
| 3 months | -5.35% | ||
| 6 months | -39.88% | ||
| Current year | -18.96% |
1 week
3.81
4.43
1 month
3.815.07
Current year
3.536.05
1 year
3.5311.36
3 years
3.53277.80
5 years
3.53331.68
10 years
3.53331.68
| Managers | Title | Age | Since |
|---|---|---|---|
John Jacobs
CEO | Chief Executive Officer | 57 | 23-01-22 |
John Trizzino
PSD | President | 64 | 14-03-09 |
James Kelly
DFI | Director of Finance/CFO | 58 | 21-08-15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Richard Rodgers
BRD | Director/Board Member | 57 | 22-10-28 |
Gregg Alton
BRD | Director/Board Member | 58 | 20-10-31 |
David Mott
BRD | Director/Board Member | 58 | 20-06-15 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.31% | 18 M€ | +2.91% | - | |
| 0.15% | 0 M€ | 0.00% | - | |
| 0.13% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 3.89 | 0.00% | 2,850,616 |
| 24-04-17 | 3.89 | -2.51% | 3,723,838 |
| 24-04-16 | 3.99 | -3.16% | 3,719,407 |
| 24-04-15 | 4.12 | -3.74% | 5,326,737 |
| 24-04-12 | 4.28 | -0.47% | 4,008,108 |
Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT
More quotes
Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The Company is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Companyâs proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.
Calendar
2024-05-06
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
3.89
USD
Average target price
15.4
USD
Spread / Average Target
+295.89%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -18.96% | 544M | |
| -1.82% | 41.36B | |
| +44.25% | 41.3B | |
| +2.56% | 39.61B | |
| -12.11% | 25.62B | |
| +3.09% | 24.09B | |
| -24.16% | 18.38B | |
| +22.12% | 11.85B | |
| -3.74% | 11.82B | |
| +7.75% | 11.07B |
- Stock Market
- Equities
- NVAX Stock
